Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temelimab extension in RRMS
NCT03239860Phase 2Terminated
- Sponsor
- GeNeuro
- Start
- Jun 2017
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of temelimab in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by GeNeuro. Primary endpoint: Long term safety of GNbAC1 at 96 weeks. Started Jun 2017; status: terminated.
02
Drugs
temelimab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03239860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239860.